Twin Peaks Wealth Advisors’s UroGen Pharma URGN Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-120	Closed	-$2.16K	–	2091
2026 Q1	$2.16K	Buy	+120	New	+$2.41K	﹤0.01%	1687
2025 Q3	–	Sell	-2	Closed	-$38	–	2018
2025 Q2	$38	Buy	+2	New	+$19	﹤0.01%	2206

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Twin Peaks Wealth Advisors's URGN Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of UroGen Pharma (URGN) in Q2 2026, closing a stake of 120 shares — an estimated $2.16K sold.

Twin Peaks Wealth Advisors first reported a position in URGN in Q2 2025 and held it in 2 quarters. The position peaked at $2.16K in Q1 2026. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Twin Peaks Wealth Advisors reported no remaining UroGen Pharma position as of Q2 2026 after selling out during the quarter.
Twin Peaks Wealth Advisors sold 120 UroGen Pharma shares in Q2 2026, an estimated $2.16K.
Twin Peaks Wealth Advisors first reported a position in UroGen Pharma in Q2 2025 and held it in 2 quarters.
Twin Peaks Wealth Advisors's UroGen Pharma position peaked at $2.16K in Q1 2026.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.